Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Matthew Herper, Stat | 07.01.2026
Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It’s a piece of science that generates as many questions as answers. They...
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Emily Baumgaetner Nunn, The New York Times | 07.20.2026
The National Institutes of Health recently announced a remarkable achievement: the world’s largest database of human genomes, a repository of information that the agency says will help usher in a new era in personalized medicine.
Scientists are already developing clinical...
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
